

Wednesday, 3 July 2024

Times are in East Africa Time (EAT)

| | Opening & Welcome Bruce Kirenga | |
|-------|---|----|
| 09:00 | Opening Talk Bruce Kirenga, MBChB, MMed, MCR, PhD, FRCP Makerere University College of Health Sciences, Uganda | |
| | Session 1: National TB Control Programs: Where Do We Stand? Chairs: Bruce Kirenga and Achilles Katamba | |
| 09:05 | An Introductory Overview Stavia Turyahabwe, MBChB, MPH Ministry of Health, Uganda | |
| 09:15 | National TB Program: Zambia Chitalu Chanda Ministry of Health, Zambia | |
| 09:35 | National TB Program: Mozambique Benedita José, MD, MSc National Tuberculosis Control Program (PNCT), Mozambique | |
| 09:55 | At the Interface of Research and Policies Nilesh Bhatt, MD, MMeD, PhD Elizabeth Glaser Pediatric AIDS Foundation, Mozambique | |
| 10:15 | Panel Discussion: What are the Barriers? | |
| 10:40 | Official Opening Uganda Minister of Health, Hon. Dr. Jane Aceng Ministry of Health, Uganda | |
| 10:50 | Coffee Break | |
| | Session 2: Diagnostics & Community Screening Chair: Stavia Turyahabwe | |
| 11:25 | Novel Algorithms, AI, and Community Contact Tracing Achilles Katamba, MBChB, DCH, MSc PhD Makerere University College of Health Sciences, Uganda | |
| 11:50 | Finding the Missing Tuberculosis Cases: Lessons Learnt From Using Artificial Intelligence Enabled Chest X-Ray System for Active TB Case Search in Communities in Lagos, Nigeria Taiwo Osatuyi, Nigeria | #1 |
| 12:00 | Introduction of X-MAP System in Bridging the Evaluation Gap in Using AI Enabled Systems for Active Case Search in Lagos, Nigeria Taiwo Osatuyi, Nigeria | #3 |
| 12:10 | Candidate Biomarker Expression in Active Tuberculosis Disease Highly Correlates With Mycobacterium Tuberculosis Bacterial Load Before and During Therapy Wilber Sabiiti, Scotland | #2 |
| 12:20 | Discussion | |
| | | |

| | Session 3: Pediatric Tuberculosis Chairs: Eric Wodubeya and Nilesh Bhatt | |
|-------|--|----|
| 13:40 | TB, Pregnancy, and the Post-Partum Period Irene Andia-Biraro, MBChB, MMeD, PhD, FCP (ECSA) Makerere University, Uganda | |
| 14:05 | TB in Children Chishala Chabala, MBChB, MSc, MMed University of Zambia, School of Medicine, Zambia | |
| 14:30 | Diagnostic Cascade Using New WHO Pediatric Treatment Decision Algorithms for Pulmonary TB in Mbarara, Uganda Maria Namulwana, Uganda | #4 |
| 14:40 | Nigeria Addressing the Challenges in Childhood Tuberculosis Diagnosis With Stool- Based Xpert Testing to Improve Childhood TB Detection Rates Omotayu Salau, Nigeria | #5 |
| 14:50 | The Use of ONEIMPACT-Nigeria as a Digital Health Platform and Innovative Strategy to Improve Tuberculosis Preventive Therapy Uptake in Children in Lagos, Nigeria Deborah Iberi Ikeh, Nigeria | #6 |
| 15:00 | Discussion | |
| 15:25 | Coffee Break | |
| | Session 4: TB, Comorbidities, and Co-Infections Chairs: Nicholas Paton and Christine Sekaggya-Wiltshire | |
| 15:55 | TB and HIV Esther Stanslaus Ngadaya, PhD, PGDHE, MD National Institute for Medical Research, Muhimbili Research centre (NIMR-Muhimbili), Tanzania | |
| 16:20 | The Burden of Tuberculous Meningitis in Greater Masaka Region-Southwestern Uganda: Findings From the Alter Trial Maria Assumpta Nakimbugwe, Uganda | #7 |
| 16:30 | Diagnostic Accuracy of Mycobacterium tuberculosis Stool Ultra in Detecting TB Among Adult People Living With HIV: A Multicentre Study George Kasule, Uganda | #8 |
| 16:40 | Utilizing a Model for Improvement Framework to Improve the Specificity of the WHO-Recommended 4-Symptom-Screen for Tuberculosis Diagnosis Among People Living With HIV in Nigeria Emeka Ezieke, Nigeria | #9 |
| 16:50 | Discussion | |
| 17:15 | Poster Viewing Gallery | |
| 18:15 | End of Day 1 | |



Thursday, 4 July 2024

Times are in East Africa Time (EAT)

| Contacts in Southern Africa Leyla Larsson, Germany O9:10 Prediction Models for Mtb Infection Among Adolescent and Adult Household Contacts in High TB Incidence Settings Edson Tawanda Marambire, Zimbabwe #11 | | Session 5: Prevention Chairs: Lloyd Mulenga and Issa Sabi | |
|---|----------------|---|-----|
| Celso Khosa, MD, PhD Instituto Nacional de Saúde, Mozambique TB Vaccines on the Horizon Frank Cobelens, MD, MSc, PhD University of Amsterdam, Amsterdam Institute of Global Health and Development, The Netherlands D9:00 Body Mass Index Trajectories and Association With Tuberculosis Risk in a Cohort of Household Contacts in Southern Africa Leyla Larsson, Germany O9:10 Prediction Models for Mtb Infection Among Adolescent and Adult Household Contacts in High TB Incidence Settings Edson Tawanda Marambire, Zimbabwe O9:20 Effect of Adjunctive N-Acetylcysteine on Biomarkers of Lung Inflammation, and Antimicrobial Activity in Adults With Pulmonary Tuberculosis Daniel Mapamba, Tanzania O9:30 Discussion O9:45 Coffee Break FAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Developpement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alllance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZO43 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 08:00 | Nyanda Elias Ntinginya, MD, MSc, PhD | |
| Frank Cobelens, MD, MSc, PhD University of Amsterdam, Amsterdam Institute of Global Health and Development, The Netherlands 99:00 Body Mass Index Trajectories and Association With Tuberculosis Risk in a Cohort of Household Contacts in Southern Africa Leyla Larsson, Germany 99:10 Prediction Models for Mtb Infection Among Adolescent and Adult Household Contacts in High TB Incidence Settings Edson Tawanda Marambire, Zimbabwe 99:20 Effect of Adjunctive N-Acetylcysteine on Biomarkers of Lung Inflammation, and Antimicrobial Activity in Adults With Pulmonary Tuberculosis Daniel Mapamba, Tanzania 99:30 Discussion 99:45 Coffee Break FAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-OO9 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGMATB (Testing BTZO43 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 08:20 | Celso Khosa, MD, PhD | |
| Contacts in Southern Africa Leyla Larsson, Germany Prediction Models for Mtb Infection Among Adolescent and Adult Household Contacts in High TB Incidence Settings Edson Tawanda Marambire, Zimbabwe 99:20 Effect of Adjunctive N-Acetylcysteine on Biomarkers of Lung Inflammation, and Antimicrobial Activity in Adults With Pulmonary Tuberculosis Daniel Mapamba, Tanzania 99:30 Discussion 99:45 Coffee Break FAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZO43 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 08:40 | Frank Cobelens, MD, MSc, PhD | |
| TB Incidence Settings Edson Tawanda Marambire, Zimbabwe 09:20 Effect of Adjunctive N-Acetylcysteine on Biomarkers of Lung Inflammation, and Antimicrobial Activity in Adults With Pulmonary Tuberculosis Daniel Mapamba, Tanzania 09:30 Discussion 09:45 Coffee Break FAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZO43 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania | 09:00 | Contacts in Southern Africa | #10 |
| Activity in Adults With Pulmonary Tuberculosis Daniel Mapamba, Tanzania 09:30 Discussion 09:45 Coffee Break FAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 09:10 | TB Incidence Settings | #11 |
| PAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 09:20 | Activity in Adults With Pulmonary Tuberculosis | #17 |
| FAST-TB Supported Session: New Drugs and New Approaches to Testing in Trials Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 09:30 | Discussion | |
| Chair: Francesca Conradie 10:15 WHO Target Regimen Profile for New Drug Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZO43 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 09:45 | Coffee Break | |
| Christian Lienhardt, MD, DTM, MSc, PhD (virtual) Institut de Recherche pour le Développement (IRD), France 10:40 Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | | | |
| Andreas Diacon, MD, PhD TASK, South Africa 11:05 Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZO43 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 10:15 | Christian Lienhardt, MD, DTM, MSc, PhD (virtual) | |
| Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa 11:30 Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | 10:40 | Clinical Trial 1: PAN-TB (Testing New DPR1 inhibitor and Sutezolid) | |
| Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania 11:55 Discussion: Innovative Approaches in Conducting Clinical Trials | | Andreas Diacon, MD, PhD | |
| | | Andreas Diacon, MD, PhD TASK, South Africa Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc | |
| 12:20 Lunch | 11:05 | Andreas Diacon, MD, PhD TASK, South Africa Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD | |
| | 11:05 11:30 | Andreas Diacon, MD, PhD TASK, South Africa Clinical Trial 2: NC-009 (Testing New Version of BDQ) Morounfolu (Folu) Olugbosi, MD, MSc TB Alliance, South Africa Clinical Trial 3: PARADIGM4TB (Testing BTZ043 and Ganfeborole) Nyanda Elias Ntinginya, MD, MSc, PhD National Institute for Medical Research (NIMR), Tanzania | |

| | Session 7: Innovations in Implementation Strategies Chair: Violeta Chihota | |
|-------|--|-----|
| 13:20 | Enhancing TB Contact Investigation: Finding the Missing TB Cases Using the Spot to Tent Onion Model Iboro Gordon, Nigeria | #13 |
| 13:30 | Artificial Intelligence (AI) screening for TB as an Effective Tool for GeneXpert (GXP) Cartridge Optimization: Comparing TB Yield From Community Active Eze Chikwu, Nigeria | #14 |
| 13:40 | Artificial Intelligence for TB Screening to Improve Active TB Case Detection Among Urban Slum, Rural and Pastoralist TB-Key Affected and Vulnerable Populations in Ethiopia Tamiru Mebrate, Ethiohpia | #15 |
| 13:50 | Patient-Centered Innovations in TB Care: A Case Study of Digital Adherence Technologies Project in Nigeria Iboro Gordon, Nigeria | #16 |
| 14:00 | Discussion: Community-Led Services | |
| 14:25 | Short Break | |
| | Session 8: How to Strengthen Collaboration? Moderator: Bruce Kirenga | |
| 14:40 | A Case Study Moses Joloba, MBChB, MS, PhD Makere University, Uganda | |
| 15:00 | Panel Discussion | |
| 15:35 | Coffee Break | |
| | Session 9: MDR-TB: What is on the Horizon? Chairs: Christine Sekaggya-Wiltshire and Nicholas Paton | |
| 16:00 | Treatment Studies Francesca Conradie, MMBCh World Health Organization, Switzerland | |
| 16:25 | Innovative Tools to Study Emerging Drug Resistance Celso Khosa, MD, PhD Instituto Nacional de Saúde, Mozambique | |
| 16:50 | Program Implications Debra Vambe, MD, MPhil, MPH Baylor College of Medicine, Global and Immigrant Health, Eswatini | |
| 17:15 | Discussion | |
| 17:25 | Closing of the Program | |